Clinical Trials Logo

Clinical Trial Summary

The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06295770
Study type Interventional
Source Mayo Clinic
Contact Angela Reinke
Phone 507-266-1047
Email Reinke.Angela@mayo.edu
Status Recruiting
Phase Phase 2
Start date June 24, 2024
Completion date May 2026

See also
  Status Clinical Trial Phase
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT02197767 - Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis Phase 2
Active, not recruiting NCT05546047 - A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients Phase 4